Apc-100

Apc-100

SCHEMBL633424

Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AR

The experimentally established mechanism targets of Apc-100. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.64
TSHR P16473 2/20 0.64
PTGS1 P23219 1/20 0.64
PTGS2 P35354 1/20 0.64
CYP1A2 P05177 1/20 0.64
MAPT P10636 3/20 0.50
LMNA P02545 3/20 0.50
USP2 O75604 2/20 0.50
CYP2C9 P11712 2/20 0.50
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
GSTP1 P09211 1/20 0.50
TTPA P49638 1/20 0.50
THRB P10828 1/20 0.50
CYP2C19 P33261 1/20 0.50
NR1I2 O75469 2/20 0.49
CCR5 P51681 1/20 0.47
ALOX5 P09917 4/20 0.45
CYP4F2 P78329 1/20 0.43
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Apc-100 SCHEMBL3134545 0.92 CYP3A4 (0.60) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL5772272 0.84 CYP3A4 (0.48) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL5796964 0.84 CYP3A4 (0.48) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL5796169 0.84 CYP3A4 (0.48) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL1285831 0.84 CYP3A4 (0.48) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL5774935 0.84 CYP3A4 (0.48) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL8259133 0.84 PTGS1 (0.45) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL4427867 0.84 CYP3A4 (0.62) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL4472285 0.83 CYP3A4 (0.61) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL14283910 0.83 CYP3A4 (0.47) CYP3A4TSHRPTGS1PTGS2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 6011 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122080172-A T cell receptor engineering transformation method and application thereof 2026-05-26 CN claimed
US-12630606-B2 Peptide deficient-MHC class I/chaperone compositions and methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-19 US claimed
CN-122067592-A Method for screening candidate CTL epitopes based on binding free energy calculation 大连大学 2026-05-19 CN claimed
CN-122070133-A Pharmaceutical compositions containing androgen receptor inhibitors/antagonists, methods and uses 苏州开拓药业股份有限公司 2026-05-19 CN claimed
EP-4740019-A1 A METHOD OF IDENTIFYING MHC-BINDING PROTEINS AND INTERACTING PEPTIDES IN A SAMPLE Immatics Biotechnologies GmbH (DE) 2026-05-13 EP claimed
EP-4739395-A2 BISPECIFIC POLYPEPTIDE MOLECULE Enara Bio Limited (GB) 2026-05-13 EP claimed
CN-122029198-A Method for purifying small multi-domain proteins 英美偌科有限公司 2026-05-12 CN claimed
US-20260126421-A1 METHOD OF DETERMINING AN AMOUNT OF WATER IN A SAMPLE USING A PHENOL COMPOUND HONEYWELL INTERNATIONAL INC. (US) 2026-05-07 US claimed
US-20260126450-A1 LIBRARY-SCALE METHODS FOR POLYPEPTIDE FUNCTIONAL ANALYSIS MASSACHUSETTS INST OF TECHNOLOGY (US) 2026-05-07 US claimed
US-20260109786-A1 CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-04-23 US claimed
EP-1727780-A1 PROCESS FOR PREPARING (METH)ACRYLIC ESTERS. BASF AKTIENGESELLSCHAFT (DE) 2006-12-06 EP claimed
US-20060105030-A1 Transdermal therapeutic system AXXONIS PHARMA AG (DE) 2006-05-18 US claimed
WO-2005082828-A1 METHOD FOR THE PRODUCTION OF (METH)ACRYLIC ACID ESTERS BASF AKTIENGESELLSCHAFT (DE) 2005-09-09 WO claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
US-6605667-B1 1,1-disubstituted ethylene monomers such as alpha-cyano-acrylates; storage stability CLOSURE MEDICAL CORPORATION 2003-08-12 US claimed
WO-2002020069-A2 ANTIOXIDANT ENRICHED ADHESIVE COMPOSITIONS AND STORAGE CONTAINERS THEREFOR CLOSURE MEDICAL CORPORATION (US) 2002-03-14 WO claimed
WO-1998034646-A2 TARGETED ANTIOXIDANTS UNIVERSITY OF HERTFORDSHIRE (GB) 1998-08-13 WO claimed
EP-0566718-A1 STABILIZERS FOR PLASTIC MATERIALS Ciba SC Holding AG (CH) 1993-10-27 EP claimed
WO-1993010175-A1 STABILIZERS FOR PLASTIC MATERIALS F. HOFFMANN-LA ROCHE AG (CH) 1993-05-27 WO claimed
EP-0445735-A1 Melanogenesis-inhibiting endermic preparation Sansho Seiyaku Co., Ltd. (JP) 1991-09-11 EP claimed